Lenvima is owned by Eisai Inc.
Lenvima contains Lenvatinib Mesylate.
Lenvima has a total of 6 drug patents out of which 0 drug patents have expired.
Lenvima was authorised for market use on 13 February, 2015.
Lenvima is available in capsule;oral dosage forms.
Lenvima can be used as method for treating thyroid carcinoma including differentiated thyroid cancer.
The generics of Lenvima are possible to be released after 26 August, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(2 years from now) | |
US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(3 years from now) | |
US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
New Indication (I) | Aug 10, 2024 |
M | Dec 19, 2024 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic